Lyell Immunopharma, Inc. (LYEL)
LYEL moved a median of 0.00% 30 minutes after news, and -0.01% by the close. How LYEL actually reacts to news — the realized, point-in-time move the market made, measured across 254 labeled events over the last three years with zero look-ahead.
LYEL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 252 |
| 30-min | 0.00% | 50% | 252 |
| 60-min | +0.24% | 54% | 254 |
| to close | -0.01% | 48% | 246 |
| Middle 50% of LYEL reactions | -1.95% to +2.07% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 254 |
Half of all Lyell Immunopharma, Inc. news events land between -1.95% and +2.07% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LYEL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 16 | -1.73% | 50% | -0.69% |
| Rating reiterations | 37 | -0.37% | 43% | -0.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how LYEL ranks against every other measured name →
That’s how LYEL usually reacts — get an email when it moves on news →Email me when LYEL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LYEL's baseline. Nothing else.
Recent LYEL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference | Press release | GlobeNewswire | -0.25% | -5.35% | |
| Form 8-K Lyell Immunopharma, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +4.75% | -3.63% | |
| Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer | Press release | GlobeNewswire | +4.75% | -3.63% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.29% | +5.07% | |
| Form 8-K Lyell Immunopharma, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +3.29% | +5.07% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 | Press release | GlobeNewswire | +3.29% | +5.07% | |
| Form EFFECT Lyell Immunopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +2.71% | -6.14% | |
| Form S-3 Lyell Immunopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | -2.39% | -5.90% | |
| Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | Press release | GlobeNewswire | +0.61% | -4.87% | |
| Form 8-K Lyell Immunopharma, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -9.96% | -6.89% | |
| Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress | Press release | GlobeNewswire | +0.37% | +0.45% | |
| Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion | Press release | GlobeNewswire | +1.56% | +0.90% | |
| Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress | Press release | GlobeNewswire | +0.54% | -7.85% | |
| Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 | Press release | GlobeNewswire | -2.12% | -0.46% | |
| Lyell Immunopharma Announces Participation in May Investor Conferences | Press release | GlobeNewswire | -0.26% | +0.94% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.57% | -5.51% | |
| Form 8-K Lyell Immunopharma, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -4.57% | -5.51% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 | Press release | GlobeNewswire | -4.57% | -5.51% | |
| Form ARS Lyell Immunopharma, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +1.62% | |
| Form DEF 14A Lyell Immunopharma, Inc. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +1.62% | |
| Form DEFA14A Lyell Immunopharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +1.62% | |
| Form EFFECT Lyell Immunopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +2.65% | +3.56% | |
| Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -0.91% | -1.04% | |
| Form S-3 Lyell Immunopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.04% | +2.50% | |
| Form 10-K Lyell Immunopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -14.24% | |
| Form 8-K Lyell Immunopharma, Inc. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -14.24% | |
| Form S-8 Lyell Immunopharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -14.24% | |
| Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results | Press release | GlobeNewswire | +0.00% | -14.24% | |
| Form 8-K Lyell Immunopharma, Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | -3.08% | +8.97% | |
| Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer | Press release | GlobeNewswire | -3.08% | +8.97% | |
| Lyell Immunopharma Announces Participation in March Investor Conferences | Press release | GlobeNewswire | +0.00% | +6.87% | |
| Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma | Press release | GlobeNewswire | +2.46% | +3.93% | |
| Form EFFECT Lyell Immunopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.27% | +1.05% | |
| Form 8-K Lyell Immunopharma, Inc. For: Dec 07 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | +9.63% | |
| Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | Press release | GlobeNewswire | -1.00% | +9.63% | |
| Form 8-K Lyell Immunopharma, Inc. For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | +9.63% | |
| Form S-3 Lyell Immunopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | -1.00% | +9.63% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.12% | — | |
| Form 8-K Lyell Immunopharma, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -0.12% | — | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 | Press release | GlobeNewswire | -0.12% | — | |
| Form 8-K Lyell Immunopharma, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +13.12% | +9.95% | |
| Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer | Press release | GlobeNewswire | +13.12% | +9.95% | |
| Form 8-K Lyell Immunopharma, Inc. For: Oct 31 | SEC filing · Form 8-K | SEC EDGAR | +2.61% | -1.90% | |
| Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition | Press release | GlobeNewswire | +2.61% | -1.90% | |
| Form 8-K Lyell Immunopharma, Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.60% | |
| Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee | Press release | GlobeNewswire | — | -0.61% | |
| Lyell Immunopharma Announces Participation in September Investor Conferences | Press release | GlobeNewswire | — | -0.61% | |
| Form EFFECT Lyell Immunopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.19% | +2.69% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +16.70% | |
| Form 8-K Lyell Immunopharma, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +16.70% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LYEL section they belong to.
Where else LYEL is measured.
LYEL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lyell Immunopharma, Inc.'s median reaction calculated?
Every labeled LYEL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 254 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of LYEL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LYEL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.